Liam R. Kugler

Liam R. Kugler

Auto-generated profile, based on publicly available information

Liam R. Kugler

University of Florida

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in The American Journal of Surgery
Verified
Journal Article
Closed access
LKLiam R. Kugler
Liam R. Kugler
GSGriffin P. Stinson
Griffin P. Stinson
VBVictoria E. Bindi
Victoria E. Bindi
YSYuriy Stukov
Yuriy Stukov
AMAngela P. Mihalic
Angela P. Mihalic
JTJanice A. Taylor
Janice A. Taylor

9 September 2025 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
ABAhmet Bilgili
Ahmet Bilgili
OSOmar M Sharaf
Omar M Sharaf
LKLiam Kugler
Liam Kugler
TKTyler Kashuv
Tyler Kashuv
ZBZachary Brennan
Zachary Brennan
JJJeffrey Phillip Jacobs
Jeffrey Phillip Jacobs
Background: This analysis evaluates the longitudinal impact of extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD) on the progression of motor delay and cognitive delay in pediatric heart transplant recipients. Methods: The United Network for Organ Sharing Registry was queried for pediatric patients (<18 years) who received a heart transplant between 2008 and 2022 and were bridged-to-transplantation with either ECMO or VAD. Patients were further stratified based on the progression of delay status pretransplant to post-transplant. Results: A total of 827 patients were included in the final VAD cohort and 68 in the final ECMO cohort with 187/827 (22.6%) and 20/68 (29.4%) having progression of delay, respectively. Patients with progression of delay were more likely than those without progression of delay to have had a stroke prior to discharge (VAD: 14/187 (7.5%) vs. 16/640 (2.5%), P = .003; ECMO: 5/20 (25%) vs. 3/48 (6.25%), P = .043). VAD patients more often developed isolated delays (motor or cognitive only), whereas patients bridged-to-transplantation on ECMO more often had combined delays, with a cumulative incidence of combined delay at 3-years of 20.0% (95% CI = 8.94–34.20). Among VAD supported patients, those with progression of delay had worse 3-year survival compared with those without (91.20% [95% CI = 87.04–95.57%] vs. 94.97% [95% CI = 93.19–96.78], log-rank P = .04). Postoperative stroke was associated with an increased risk of progression of delay (OR = 2.39 [95% CI = 1.13–5.02] P = .021), and progression of delay was found to be an independent predictor of mortality (HR = 2.10 [95% CI = 1.35–3.25], P < .001). Conclusions: While overall rates of neurodevelopmental delay are similar between those bridged-to-transplantation with ECMO or VAD, the type of delay and associated survival varies.

9 June 2025 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
MBMark Steven Bleiweis
Mark Steven Bleiweis
DGDipankar Gupta
Dipankar Gupta
FFFrederick J. Fricker
Frederick J. Fricker
JPJoseph Philip
Joseph Philip
GPGiles J. Peek
Giles J. Peek
JJJeffrey Phillip Jacobs
Jeffrey Phillip Jacobs
Background: We reviewed our management strategy and outcome data for all 112 patients with congenital heart disease (CHD) who underwent cardiac transplantation at University of Florida from January 2011, to January 2022, and evaluated the impact of a pretransplant ventricular assist device (VAD). Methods: Continuous variables are presented as mean (SD); median [interquartile range] (range); categorical variables are presented as N (%). Univariable associations with long-term survival were assessed with Cox proportional hazards models. The impact of pretransplant VAD on survival was estimated with multivariable models. Results: Pretransplant VAD was present in 24 of 112 patients who underwent cardiac transplantation (21.4%). Patients with a VAD were younger (years): 3.0 (3.8); 1 [0.5,6] (0.1,14) versus 12.9 (14.9); 9 [0.6,19] (0.1,58), P  = .008. More patients with a VAD had prior cardiac operations: 24 of 24 (100%) versus 71 of 88 (80.7%), P  = .021 and were more likely to receive an ABO-incompatible transplant: 6 of 24 (25%) versus 7 of 88 (8%), P  = .032. Univariable associations with long-term mortality include: Number of prior cardiac surgeries-hazard ratio (HR) multiplies by 1.2 for each additional surgery (1.02-1.44), P  = .029. Pretransplant renal dysfunction - HR = 2.8 (1.21-6.68), P  = .017. Cardiopulmonary bypass (CPB) time at transplant: HR multiplies by 1.1 for each 10 min increase above the minimum CPB time in this series (1.03-1.19), P  = .008. In multivariable analysis, pretransplant VAD does not impact survival when controlling for each one of the factors shown in univariable analysis to be associated with long-term survival. Kaplan-Meier five-year survival (95% confidence interval) is 77.4% (68.4%-87.5%) for all patients; 76.5% (66.7%-87.9%) without pretransplant VAD and 84.3% (69.3%-99.9%) with pretransplant VAD ( P  = .436). Conclusion: Our single-institution analysis of 112 patients with CHD undergoing cardiac transplantation over 11.25 years reveals similar survival in patients with (n = 24) and without (n = 88) pretransplant VAD. The presence of a pretransplant VAD is not a risk factor for survival after transplantation in patients with CHD.

26 November 2025 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
MBMark Steven Bleiweis
Mark Steven Bleiweis
FFFrederick J. Fricker
Frederick J. Fricker
DGDipankar Gupta
Dipankar Gupta
BPBiagio “Bill” A. Pietra
Biagio “Bill” A. Pietra
JCJohn-Anthony Coppola
John-Anthony Coppola
JJJeffrey Phillip Jacobs
Jeffrey Phillip Jacobs
Purpose: We reviewed all 181 patients with pediatric and/or congenital heart disease (CHD) who underwent cardiac transplantation at the University of Florida from January 1, 2011, to March 1, 2022, and compared those with CHD with those who had acquired heart disease (AHD). Methods: Patient characteristics were assessed, stratified by CHD versus AHD. Continuous variables are presented as mean (SD); median[interquartile range](range). Categorical variables are presented as N (%). Univariable associations with long-term mortality were assessed with a Cox proportional-hazards model. The impact of CHD versus AHD on mortality was estimated with multivariable models. The Kaplan-Meier method was applied to estimate survival stratified by CHD versus AHD status. Results: Congenital heart disease was present in 112/181 patients = 61.9% of the total cohort. Acquired heart disease was present in 69/181 = 38.1%. More patients with CHD had prior cardiac surgery (95/112 = 84.8% vs 35/69 = 50.7%, P < .0001) and pretransplant liver dysfunction (19/112 = 17.0% vs 4/69 = 5.8%, P = .037). Congenital heart disease patients had longer bypass times (minutes): 148 (55.2); 137 [113-174] (72-526) versus 108 (40.3);101 [81-125] (59-300), P < .0001; longer cross clamp time (minutes): 85.9 (21.2); 85 [73-100] (49-152) versus 66.3 (14.7); 65 [55-75] (44-106), P < .0001; and lower minimum temperature on bypass (°C): 27.4 (4.3); 28 [24-31] (19-34) versus 31.6 (3.1); 32 [31-34] (20-36), P < .0001. Posttransplant length of stay (days) was longer in CHD patients: 34.5 (26.8); 27 [19-40] (3-158) versus 29.7 (48.2); 18 [15-26] (0-343), P = .0001. In multivariable analysis, CHD remained a risk factor for mortality after controlling for all variables significant in univariable modeling. Overall Kaplan-Meier 5-year survival in all 181 patients (95% confidence interval) = 85.8% (80.0%-92.1%). Kaplan-Meier 5-year survival = 77.4% (68.4%-87.5%) in CHD and 98.5% (95.6%-99.9%) in AHD, P < .0001. Conclusion: Congenital heart disease is a risk factor for mortality after cardiac transplantation. Efforts must be made to understand and mitigate this risk.